| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Eve-Isabelle Pécheur | |
| François Penin | |||
| Elodie Teissier | |||
| P2860 | cites work | HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activity | Q21076115 |
| Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection | Q21245138 | ||
| Mechanisms of viral entry: sneaking in the front door | Q22252690 | ||
| A small-molecule dengue virus entry inhibitor | Q22309806 | ||
| Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins | Q22570477 | ||
| Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein | Q22808780 | ||
| A small molecule fusion inhibitor of dengue virus | Q22808782 | ||
| Identification of hepatoprotective flavonolignans from silymarin | Q24600492 | ||
| HIV-1 entry inhibitors: an overview | Q24645525 | ||
| Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol | Q24653452 | ||
| Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion | Q24656213 | ||
| Assembly of endocytic machinery around individual influenza viruses during viral entry | Q24669815 | ||
| Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes | Q24673768 | ||
| Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin | Q24680353 | ||
| Peptide inhibitors of dengue virus and West Nile virus infectivity | Q24813811 | ||
| Preclinical Evaluation of Two Neutralizing Human Monoclonal Antibodies against Hepatitis C Virus (HCV): a Potential Treatment To Prevent HCV Reinfection in Liver Transplant Patients | Q27473046 | ||
| Hepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis | Q27473290 | ||
| A ligand-binding pocket in the dengue virus envelope glycoprotein | Q27477685 | ||
| Structural basis of viral invasion: lessons from paramyxovirus F | Q27481675 | ||
| Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion | Q27485039 | ||
| A virocidal amphipathic -helical peptide that inhibits hepatitis C virus infection in vitro | Q27485575 | ||
| The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry | Q27485588 | ||
| Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus | Q27485703 | ||
| Viral membrane fusion | Q27486639 | ||
| Structures and Mechanisms of Viral Membrane Fusion Proteins: Multiple Variations on a Common Theme | Q27487974 | ||
| Low pH-dependent Hepatitis C Virus Membrane Fusion Depends on E2 Integrity, Target Lipid Composition, and Density of Virus Particles | Q27489056 | ||
| Human occludin is a hepatitis C virus entry factor required for infection of mouse cells | Q27490169 | ||
| Amphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral Entry | Q27490785 | ||
| The Disulfide Bonds in Glycoprotein E2 of Hepatitis C Virus Reveal the Tertiary Organization of the Molecule | Q27490948 | ||
| A broad-spectrum antiviral targeting entry of enveloped viruses | Q27491286 | ||
| Peptide Inhibitors of Dengue-Virus Entry Target a Late-Stage Fusion Intermediate | Q27491339 | ||
| Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation | Q27643140 | ||
| Mechanism by which the lectin actinohivin blocks HIV infection of target cells | Q27657228 | ||
| Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin | Q39303806 | ||
| Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion | Q39697277 | ||
| Multiple effects of silymarin on the hepatitis C virus lifecycle | Q39698364 | ||
| Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes | Q39723280 | ||
| Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo | Q39912694 | ||
| EWI-2wint--a host cell factor inhibiting hepatitis C virus entry. | Q39914715 | ||
| Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans | Q40261250 | ||
| Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation | Q40298802 | ||
| Antiviral activity of chondroitin sulphate E targeting dengue virus envelope protein | Q40348272 | ||
| Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes | Q40364883 | ||
| Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. | Q40468928 | ||
| Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. | Q40536971 | ||
| Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level | Q42065660 | ||
| Gumming up the works: DNA polymers as HCV entry inhibitors | Q42426768 | ||
| Actinohivin: specific amino acid residues essential for anti-HIV activity | Q42907167 | ||
| Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. | Q42981378 | ||
| Lamiridosins, hepatitis C virus entry inhibitors from Lamium album. | Q42992652 | ||
| A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients | Q42993950 | ||
| Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes | Q42999009 | ||
| Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies | Q43041465 | ||
| Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells | Q43205377 | ||
| Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions | Q44488145 | ||
| Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy | Q45376579 | ||
| Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida | Q45378078 | ||
| Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. | Q45396940 | ||
| Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. | Q46834318 | ||
| Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States | Q46925884 | ||
| Adamantane resistance in influenza A. | Q46956251 | ||
| Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment | Q46989111 | ||
| Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein | Q27658463 | ||
| Production of infectious hepatitis C virus in tissue culture from a cloned viral genome | Q27860899 | ||
| Replication of hepatitis C virus | Q27860957 | ||
| Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry | Q28131832 | ||
| The structural biology of type I viral membrane fusion | Q28188215 | ||
| HIV entry and its inhibition | Q28273919 | ||
| Arbidol: a broad-spectrum antiviral compound that blocks viral fusion | Q28275353 | ||
| Influenza M2 proton channels | Q28281767 | ||
| Identification of terfenadine as an inhibitor of human CD81-receptor HCV-E2 interaction: synthesis and structure optimization | Q28284214 | ||
| Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol | Q28301644 | ||
| Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein | Q28471835 | ||
| HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranes | Q28473380 | ||
| A Novel Small Molecule Inhibitor of Hepatitis C Virus Entry | Q28475468 | ||
| Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol | Q28476811 | ||
| Distribution and three-dimensional structure of AIDS virus envelope spikes | Q29617562 | ||
| An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A | Q29620628 | ||
| Virus membrane-fusion proteins: more than one way to make a hairpin | Q29620769 | ||
| Host envelope glycoprotein processing proteases are indispensable for entry into human cells by seasonal and highly pathogenic avian influenza viruses | Q30229199 | ||
| Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline? | Q30341187 | ||
| Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. | Q30353535 | ||
| Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells | Q30357092 | ||
| Identification and characterisation of a novel anti-viral peptide against avian influenza virus H9N2. | Q30377821 | ||
| Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors | Q30386796 | ||
| Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120. | Q30909988 | ||
| Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage | Q31454800 | ||
| A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry | Q33531362 | ||
| Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses | Q33558767 | ||
| Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein | Q33717942 | ||
| Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody | Q33798442 | ||
| Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin | Q33826751 | ||
| The molecular basis of the specific anti-influenza action of amantadine | Q33931939 | ||
| Viral entry inhibitors targeted to the membrane site of action. | Q33990602 | ||
| Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions | Q34004118 | ||
| Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase | Q34020427 | ||
| A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells. | Q34051627 | ||
| Influenza A: understanding the viral life cycle | Q34089400 | ||
| Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses | Q34182763 | ||
| Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers | Q34607768 | ||
| Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies | Q34634347 | ||
| Class III viral membrane fusion proteins | Q34789408 | ||
| Drug-drug interactions of silymarin on the perspective of pharmacokinetics | Q34890751 | ||
| Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development | Q35137168 | ||
| Orally active fusion inhibitor of respiratory syncytial virus | Q35547902 | ||
| Class II virus membrane fusion proteins | Q36346783 | ||
| Cell entry of hepatitis C virus | Q36385222 | ||
| Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions | Q36525116 | ||
| Herbal medicine in the treatment of liver diseases | Q36748782 | ||
| Current pharmacotherapeutic treatment options in Parkinson's disease | Q36857140 | ||
| Lipids as modulators of membrane fusion mediated by viral fusion proteins | Q36946651 | ||
| Hepatitis C virus entry into host cells | Q36959983 | ||
| Distribution and dynamics of adamantanes in a lipid bilayer | Q37008274 | ||
| Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency | Q37153758 | ||
| The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity | Q37448171 | ||
| Evolution of prophylaxis: MoAb, siRNA, vaccine, and small molecules | Q37570954 | ||
| Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion | Q37585515 | ||
| The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership | Q37609487 | ||
| Viral entry mechanisms: the increasing diversity of paramyxovirus entry | Q37624858 | ||
| Development of novel therapies for hepatitis C. | Q37736815 | ||
| Viral proteins function as ion channels. | Q37755567 | ||
| New perspectives in HCV therapy: entry inhibitors. | Q37760237 | ||
| Essential regions for antiviral activities of actinohivin, a sugar-binding anti-human immunodeficiency virus protein from an actinomycete | Q38327540 | ||
| Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope | Q38343814 | ||
| Actinohivin, a novel anti-HIV protein from an actinomycete that inhibits syncytium formation: isolation, characterization, and biological activities | Q38943968 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anti-HIV agents | Q50377208 |
| P304 | page(s) | 221-250 | |
| P577 | publication date | 2010-12-30 | |
| P1433 | published in | Molecules | Q151332 |
| P1476 | title | Targeting cell entry of enveloped viruses as an antiviral strategy | |
| P478 | volume | 16 |
| Q39152233 | "Fusion and binding inhibition" key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches. |
| Q39788993 | 5-(Perylen-3-yl)ethynyl-arabino-uridine (aUY11), an arabino-based rigid amphipathic fusion inhibitor, targets virion envelope lipids to inhibit fusion of influenza virus, hepatitis C virus, and other enveloped viruses |
| Q39156048 | A Review of Functional Motifs Utilized by Viruses. |
| Q35956838 | A generic screening platform for inhibitors of virus induced cell fusion using cellular electrical impedance |
| Q30422931 | A new player in the puzzle of filovirus entry |
| Q36297991 | A suite of modular fluorescence assays interrogate the human immunodeficiency virus glycoprotein-41 coiled coil and assist in determining binding mechanism of low molecular weight fusion inhibitors |
| Q37685760 | Acid phosphatase 2 (ACP2) is required for membrane fusion during influenza virus entry |
| Q37951610 | Amphipathic properties of HIV-1 gp41 fusion inhibitors |
| Q95290815 | Antiviral Peptides: Identification and Validation |
| Q40307920 | Antiviral agents targeting glycans on dengue virus E-glycoprotein |
| Q40143919 | Antiviral and Antioxidant Activities of Sulfated Galactomannans from Plants of Caatinga Biome |
| Q30391416 | Antivirals for Respiratory Viral Infections: Problems and Prospects |
| Q34040731 | Arbidol as a broad-spectrum antiviral: an update |
| Q33696539 | Blocking interaction of viral gp120 and CD4-expressing T cells by single-stranded DNA aptamers |
| Q37065151 | Cell surface assembly of HIV gp41 six-helix bundles for facile, quantitative measurements of hetero-oligomeric interactions |
| Q38107673 | Chikungunya virus: an update on antiviral development and challenges |
| Q40288667 | Computational identification of self-inhibitory peptides from envelope proteins |
| Q36946831 | Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay |
| Q34253013 | Discovery and SAR study of piperidine-based derivatives as novel influenza virus inhibitors |
| Q34522341 | Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. |
| Q36842185 | Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells |
| Q99201268 | How can nanotechnology help to combat COVID-19? Opportunities and urgent need |
| Q35860797 | Identification of Peptide Inhibitors of Enveloped Viruses Using Support Vector Machine |
| Q40159006 | Identification of sequence motifs involved in Dengue virus-host interactions |
| Q22337991 | Inhibitors of tick-borne flavivirus reproduction from structure-based virtual screening |
| Q40189080 | Interaction of Flaviviruses with Reproduction Inhibitors Binding in β-OG Pocket: Insights from Molecular Dynamics Simulations |
| Q38524164 | Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides. |
| Q27026314 | Multiscale perspectives of virus entry via endocytosis |
| Q53601817 | Naïve Human Antibody Libraries for Infectious Diseases. |
| Q84315466 | Peptide-Protein Interaction Studies of Antimicrobial Peptides Targeting Middle East Respiratory Syndrome Coronavirus Spike Protein: An In Silico Approach |
| Q40218035 | Prediction of HBF-0259 interactions with hepatitis B Virus receptors and surface antigen secretory factors |
| Q92983162 | Rice stripe virus hitchhikes the vector insect vitellogenin ligand-receptor pathway for ovary entry |
| Q98389656 | SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells |
| Q90737186 | Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus |
| Q59355547 | Surfactin Inhibits Membrane Fusion during Invasion of Epithelial Cells by Enveloped Viruses |
| Q55084371 | The Antiviral Drug Arbidol Inhibits Zika Virus. |
| Q40026277 | The Location of the Protonated and Unprotonated Forms of Arbidol in the Membrane: A Molecular Dynamics Study. |
| Q28271798 | The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses |
Search more.